Health Care

Shares of Moderna Inc (MRNA.O) rose more than 5% on Wednesday after analysts said a $1.5 billion coronavirus vaccine supply agreement with the U.S. government could lead to similar deals with other countries.

Humana Inc. announces actions designed to help provide financial and administrative relief for the health care provider community facing unprecedented strain during the coronavirus pandemic.

The world’s biggest Covid-19 vaccine study got underway Monday with the first of 30,000 planned volunteers helping to test shots created by the U.S. government. There’s still no guarantee that the experimental vaccine, developed by the National Institutes of Health and Moderna, will really protect.

Shares of Moderna Inc fell nearly 10% after it lost a bid to invalidate a U.S. patent owned by Arbutus Biopharma that poses a potential obstacle to Moderna’s efforts to develop next-generation vaccines, including a coronavirus vaccine.

Electrical equipment maker Philips said a recent surge in orders for scanners and other medical equipment should enable group sales and margins to rebound over the next six months from a slump in the second quarter.

Uber Technologies Inc has quietly launched a service to give public health officials quick access to data on drivers and riders presumed to have come into contact with someone infected with COVID-19, company officials told Reuters.

Testees complain about waiting more than 10 days as coronavirus cases surge in U.S.

DoorDash announced a partnership Thursday with Walgreens Boots Alliance to deliver over-the-counter medication and other products from the drugstore chain.

Abbott Laboratories said demand is surging for its portfolio of tests for the coronavirus strain Covid-19 as the pandemic triggers unprecedented need for its diagnostic products around the world.

Moderna Inc’s (MRNA.O) shares rose 17% on Wednesday after a small-scale study showed its experimental COVID-19 vaccine produced high levels of virus-killing antibodies, bolstering hopes the shot could prove effective in later stages of testing.